Scalper1 News
Valeant Pharmaceuticals (VRX) issued guidance below expectations Wednesday, but Valeant stock rose anyway as the company detailed its plans, at its annual investor day. Valeant cut its Q4 guidance, a move that was widely expected since it ended its relationship with specialty pharmacy Philidor after the latter was accused of misconduct and fraud. Valeant said that sales will be at least $450 million lower than previously forecast, with the range Scalper1 News
Scalper1 News